Zydus Lifesciences Q1 FY27 Results Analysis: PAT Falls 36%, EBITDA Margin Compresses 770 bps (ZYDUSLIFE)

Zydus Lifesciences Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 8,017.00 Cr (+21.96% YoY) and PAT growth of -35.93% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Revenue grew 22% YoY to a record Rs.8,017 Cr, driven by acquisitions, but margins compressed sharply (EBITDA margin down 770 bps) and PAT declined 36% due to integration costs, higher employee and finance costs, and US generic pricing pressure. Management's FY27 guidance of >24% EBITDA margin was achieved at the lower end, but organic pharma profitability remains under strain.

Key Investment Insights

Key Positives

• Consolidated revenue grew 21.96% YoY to Rs.8,017.0 Cr, highest Q1 revenue on record
• Consumer products revenue surged 67.45% YoY to Rs.1,435.9 Cr, driven by Comfort Click acquisition
• Medical technologies revenue increased from Rs.2 Cr to Rs.283 Cr due to Amplitude Surgical consolidation
• Pharma segment revenue grew 10.22% YoY to Rs.6,298.1 Cr despite US generic pricing pressure
• Company completed Assertio acquisition on June 16, 2026, adding ~15 days of revenue
• Normalized PAT (excluding exceptional items) estimated at Rs.953.1 Cr

Risk Factors

• EBITDA margin compressed 770 bps YoY to 24.07%
• PAT (to owners) declined 35.93% YoY to Rs.939.8 Cr
• Pharma segment EBIT margin fell 1,263 bps YoY to 19.77% due to US generic competition and acquisition costs
• Finance costs surged 84.2% YoY to Rs.156 Cr due to acquisition debt
• Employee costs rose 36.1% YoY, outpacing revenue growth
• Depreciation & amortisation jumped 133% YoY to Rs.555 Cr, partly due to Mirabegron amortisation